Imprivata Expands Behavioral Monitoring for Drug Diversion to the Canadian Market
The company’s solution helps healthcare organizations ensure compliance and reduce risk with improved visibility into drug diversion
Waltham, Mass – March 21, 2023 – Imprivata, the digital identity company for life- and mission-critical industries, today announced the availability of its behavioral monitoring for drug diversion intelligence in Canada, building on its widespread adoption in the US. As a key component to the Imprivata Digital Identity Framework, it combines artificial intelligence (AI) and machine learning (ML) to uncover drug diversion and spot anomalous behavior for improved patient safety and compliance.
Drug diversion can be defined as any act or deviation of a prescription drug from its intended patient to that of another person for illicit use. Canadian data suggest that diversion of controlled medications from hospitals is on the rise, with more than 3,000 hospital pharmacies reporting incidents involving lost or stolen controlled substances, mostly opioids. Imprivata behavioral monitoring supports a proactive approach to uncovering and remediating drug diversion by ingesting hundreds of data sources, such as EHRs, CRMs, HR applications, and pharmaceutical dispensing systems, and applies data science to accurately identify anomalous behavior.
“Drug diversions inflict a devastating toll and represent a severe breach of security and patient privacy,” said Dr. Sean Kelly, Chief Medical Officer and Sr. VP of Customer Strategy for Healthcare at Imprivata. “We’re excited to offer Canadian healthcare organizations a powerful solution to spot diversion and cultivate a culture of trust with patients –the most fundamental element of the healthcare relationship.”
With drug diversion intelligence, healthcare organizations streamline their program by managing the full lifecycle of drug diversion –from detection and investigation to remediation, reporting, and prevention –in a single solution. In addition to its technology offering, Imprivata provides drug diversion monitoring services to extend resource-constrained teams with experts trained in dispensing and clinical data analysis. Find out more by visiting www.Imprivata.com.
Imprivata is the digital identity company for life- and mission-critical industries, redefining how organizations solve complex workflow, security, and compliance challenges with solutions that protect critical data and applications without workflow disruption. Its platform of interoperable identity, authentication, and access management solutions enable organizations in over 45 countries to fully manage and secure all enterprise and third-party digital identities by establishing trust between people, technology, and information. For more information, visit www.imprivata.com.